35 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
25
Discovery of Highly Potent and Selective EZH2 Covalent Inhibitors via Incorporating Basic Amines.
Sun Yat-Sen University
7
Design, synthesis, and antitumor activity of NSDs inhibitors targeting lung squamous cell carcinoma.
Peking University
32
One stone two birds: Introducing piperazine into a series of nucleoside derivatives as potent and selective PRMT5 inhibitors.
Ocean University of China
21
Rational fragment-based design of compounds targeting the PWWP domain of the HRP family.
KU Leuven
2
Discovery of SET domain-binding primary alkylamine-tethered degraders for the simultaneous degradation of NSD2-long and RE-IIBP isoforms.
Chinese Academy of Sciences
31
Inhibitors targeting the PWWP domain-containing proteins.
Central China Normal University
2
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.
University of Cambridge
10
Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation.
Epizyme, Inc.
2
Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor.
Daiichi Sankyo Co., Ltd
40
Discovery of a Highly Potent and Selective Inhibitor Targeting Protein Lysine Methyltransferase NSD2.
Sun Yat-Sen University
12
An Adenosine Analogue Library Reveals Insights into Active Sites of Protein Arginine Methyltransferases and Enables the Discovery of a Selective PRMT4 Inhibitor.
Purdue University
31
Discovery of a Highly Potent Lysine Methyltransferases G9a/NSD2 Dual Inhibitor to Treat Solid Tumors.
Sun Yat-Sen University
29
Recent advances in targeting histone H3 lysine 36 methyltransferases for cancer therapy.
China Pharmaceutical University
36
Structure-based discovery of a new series of nucleoside-derived ring-opening PRMT5 inhibitors.
University of Chinese Academy of Sciences
25
Discovery of potent small molecule inhibitors of histone lysine methyltransferase NSDs.
Jiangsu University of Technology
2
Identification of Novel Potent NSD2-PWWP1 Ligands Using Structure-Based Design and Computational Approaches.
AstraZeneca
1
Discovery of LLC0424 as a Potent and Selective in Vivo NSD2 PROTAC Degrader.
Shanghai Institute of Organic Chemistry
20
Recent advances in nuclear receptor-binding SET domain 2 (NSD2) inhibitors: An update and perspectives.
China Pharmaceutical University
18
NSD3: Advances in cancer therapeutic potential and inhibitors research.
Peking University
33
Drug Discovery Targeting Nuclear Receptor Binding SET Domain Protein 2 (NSD2).
University of Texas Medical Branch (UTMB)
17
Discovery of a New-Generation S-Adenosylmethionine-Noncompetitive Covalent Inhibitor Targeting the Lysine Methyltransferase Enhancer of Zeste Homologue 2.
Sun Yat-Sen University
47
Structural Modification and Pharmacological Evaluation of Substituted Quinoline-5,8-diones as Potent NSD2 Inhibitors.
Shanghai Jiao Tong University
38
Structure-Aided Design, Synthesis, and Biological Evaluation of Potent and Selective Non-Nucleoside Inhibitors Targeting Protein Arginine Methyltransferase 5.
Sun Yat-Sen University
3
Discovery of a First-in-Class Degrader for Nuclear Receptor Binding SET Domain Protein 2 (NSD2) and Ikaros/Aiolos.
Icahn School Of Medicine At Mount Sinai
39
Structure-Based Discovery of a Series of NSD2-PWWP1 Inhibitors.
Chinese Academy of Sciences
44
5-Aminonaphthalene derivatives as selective nonnucleoside nuclear receptor binding SET domain-protein 2 (NSD2) inhibitors for the treatment of multiple myeloma.
Chinese Academy of Sciences
14
Discovery of Small-Molecule Antagonists of the PWWP Domain of NSD2.
University of Toronto
9
Computational discovery and biological evaluation of novel inhibitors targeting histone-lysine N-methyltransferase SET7.
China Pharmaceutical University
13
Novel inhibitors of As(III) S-adenosylmethionine methyltransferase (AS3MT) identified by virtual screening.
AstraZeneca
2
FUSED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF
Jiangsu Hengrui Pharmaceuticals
37
Sulfonamide-substituted cyanopyrrolidines with activity as DUB inhibitors
Mission Therapeutics
8
Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
Merck Sharpe & Dohme